Status:
COMPLETED
Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research
Lead Sponsor:
University of Zurich
Conditions:
Recurrent Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy). Gefitinib is a s...
Detailed Description
Glioblastoma (GBM) patients who relapse and are in good performance status, without serious neurological deficits are offered secondary surgery and participation in the trial. Eligible patients must h...
Eligibility Criteria
Inclusion
- recurrent glioblastoma
- informed consent
- reoperation planned
- fresh frozen sample obtainable
Exclusion
- enzyme inducing antiepileptic drugs
- pregnancy or breast feeding
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00250887
Start Date
July 1 2005
End Date
May 1 2007
Last Update
October 23 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zürich
Zurich, Canton of Zurich, Switzerland, 8091